Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm Licenses RNAi Technology from MIT

NEW YORK (GenomeWeb News) – Intradigm Corporation has licensed rights to a nucleic acid delivery patent from the Massachusetts Institute of Technology for use in RNAi drug development.
 
The Palo Alto-based company said the IP it has licensed covers a broad range of biodegradable polymer structures that are used in delivering RNAi-based therapeutics. It added that the license would enable it to pursue applications for its NanoPlex technology across a broader range of therapeutic indications.
 
Intradigm’s RNAi Nanoplex technology is made of an active siRNA molecule and a biodegradable polycationic polymer.
 
The company said it will use the licensed technology to “identify, develop, and commercialize optimal delivery platforms.”
 
 Financial terms of the agreement were not released.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.